179 related articles for article (PubMed ID: 17505056)
1. Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P.
Dhir V; Ivison HE; Krone N; Shackleton CH; Doherty AJ; Stewart PM; Arlt W
Mol Endocrinol; 2007 Aug; 21(8):1958-68. PubMed ID: 17505056
[TBL] [Abstract][Full Text] [Related]
2. Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.
Jin Y; Chen M; Penning TM; Miller WL
Biochem J; 2015 May; 468(1):25-31. PubMed ID: 25728647
[TBL] [Abstract][Full Text] [Related]
3. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE; Nicolo C; Pandey AV
Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
[TBL] [Abstract][Full Text] [Related]
4. Combined homozygous 21 hydroxylase with heterozygous P450 oxidoreductase mutation in a Saudi boy presented with hypertension.
Aljabri A; Alnaim F; Alsaleh Y
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32994263
[TBL] [Abstract][Full Text] [Related]
5. Genetics of congenital adrenal hyperplasia.
Krone N; Arlt W
Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):181-92. PubMed ID: 19500762
[TBL] [Abstract][Full Text] [Related]
6. Deletion of P399_E401 in NADPH cytochrome P450 oxidoreductase results in partial mixed oxidase deficiency.
Flück CE; Mallet D; Hofer G; Samara-Boustani D; Leger J; Polak M; Morel Y; Pandey AV
Biochem Biophys Res Commun; 2011 Sep; 412(4):572-7. PubMed ID: 21843508
[TBL] [Abstract][Full Text] [Related]
7. P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
Burkhard FZ; Parween S; Udhane SS; Flück CE; Pandey AV
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):38-50. PubMed ID: 27068427
[TBL] [Abstract][Full Text] [Related]
8. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase.
Pandey AV; Kempná P; Hofer G; Mullis PE; Flück CE
Mol Endocrinol; 2007 Oct; 21(10):2579-95. PubMed ID: 17595315
[TBL] [Abstract][Full Text] [Related]
9. Pubertal presentation in seven patients with congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
Idkowiak J; O'Riordan S; Reisch N; Malunowicz EM; Collins F; Kerstens MN; Köhler B; Graul-Neumann LM; Szarras-Czapnik M; Dattani M; Silink M; Shackleton CH; Maiter D; Krone N; Arlt W
J Clin Endocrinol Metab; 2011 Mar; 96(3):E453-62. PubMed ID: 21190981
[TBL] [Abstract][Full Text] [Related]
10. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.
Huang N; Pandey AV; Agrawal V; Reardon W; Lapunzina PD; Mowat D; Jabs EW; Van Vliet G; Sack J; Flück CE; Miller WL
Am J Hum Genet; 2005 May; 76(5):729-49. PubMed ID: 15793702
[TBL] [Abstract][Full Text] [Related]
11. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect.
Marohnic CC; Panda SP; McCammon K; Rueff J; Masters BS; Kranendonk M
Drug Metab Dispos; 2010 Feb; 38(2):332-40. PubMed ID: 19884324
[TBL] [Abstract][Full Text] [Related]
12. Concomitant mutations in the P450 oxidoreductase and androgen receptor genes presenting with 46,XY disordered sex development and androgenization at adrenarche.
Idkowiak J; Malunowicz EM; Dhir V; Reisch N; Szarras-Czapnik M; Holmes DM; Shackleton CH; Davies JD; Hughes IA; Krone N; Arlt W
J Clin Endocrinol Metab; 2010 Jul; 95(7):3418-27. PubMed ID: 20410220
[TBL] [Abstract][Full Text] [Related]
13. P450 oxidoreductase deficiency - a new form of congenital adrenal hyperplasia.
Flück CE; Pandey AV; Huang N; Agrawal V; Miller WL
Endocr Dev; 2008; 13():67-81. PubMed ID: 18493134
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biochemical consequences of p450 oxidoreductase deficiency.
Flück CE; Pandey AV
Endocr Dev; 2011; 20():63-79. PubMed ID: 21164260
[TBL] [Abstract][Full Text] [Related]
15. P450 oxidoreductase deficiency: a new disorder of steroidogenesis.
Miller WL; Huang N; Pandey AV; Flück CE; Agrawal V
Ann N Y Acad Sci; 2005 Dec; 1061():100-8. PubMed ID: 16467261
[TBL] [Abstract][Full Text] [Related]
16. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
[TBL] [Abstract][Full Text] [Related]
17. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism.
Flück CE; Mullis PE; Pandey AV
Biochem Biophys Res Commun; 2010 Oct; 401(1):149-53. PubMed ID: 20849814
[TBL] [Abstract][Full Text] [Related]
18. Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency.
Scott RR; Gomes LG; Huang N; Van Vliet G; Miller WL
J Clin Endocrinol Metab; 2007 Jun; 92(6):2318-22. PubMed ID: 17389698
[TBL] [Abstract][Full Text] [Related]
19. Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype.
McCammon KM; Panda SP; Xia C; Kim JJ; Moutinho D; Kranendonk M; Auchus RJ; Lafer EM; Ghosh D; Martasek P; Kar R; Masters BS; Roman LJ
J Biol Chem; 2016 Sep; 291(39):20487-502. PubMed ID: 27496950
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
